Share-based Payment Arrangement, Expense of Vor Biopharma Inc. from 31 Mar 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Vor Biopharma Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2020 to 30 Sep 2025.
  • Vor Biopharma Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $8,029,000, a 255% increase year-over-year.
  • Vor Biopharma Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $13,515,000, a 35% increase year-over-year.
  • Vor Biopharma Inc. annual Share-based Payment Arrangement, Expense for 2024 was $9,847,000, a 26% decline from 2023.
  • Vor Biopharma Inc. annual Share-based Payment Arrangement, Expense for 2023 was $13,362,000, a 25% increase from 2022.
  • Vor Biopharma Inc. annual Share-based Payment Arrangement, Expense for 2022 was $10,695,000, a 148% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Vor Biopharma Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $13,515,000 $8,029,000 +$5,765,000 +255% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $7,750,000 $1,844,000 -$949,000 -34% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $8,699,000 $1,933,000 -$1,148,000 -37% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $9,847,000 $1,709,000 -$185,000 -9.8% 01 Oct 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
Q3 2024 $10,032,000 $2,264,000 -$898,000 -28% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $10,930,000 $2,793,000 -$1,445,000 -34% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $12,375,000 $3,081,000 -$987,000 -24% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $13,362,000 $1,894,000 -$1,985,000 -51% 01 Oct 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
Q3 2023 $15,347,000 $3,162,000 -$167,000 -5% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $15,514,000 $4,238,000 +$2,497,000 +143% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $13,017,000 $4,068,000 +$2,322,000 +133% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $10,695,000 $3,879,000 +$2,676,000 +222% 01 Oct 2022 31 Dec 2022 10-K 20 Mar 2024 2023 FY
Q3 2022 $8,019,000 $3,329,000 +$2,175,000 +188% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $5,844,000 $1,741,000 +$674,000 +63% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $5,170,000 $1,746,000 +$855,000 +96% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $4,315,000 $1,203,000 +$609,000 +103% 01 Oct 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
Q3 2021 $3,706,000 $1,154,000 +$671,000 +139% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $3,035,000 $1,067,000 +$914,000 +597% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $2,121,000 $891,000 +$779,000 +696% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $1,342,000 $594,000 01 Oct 2020 31 Dec 2020 10-K 14 Mar 2022 2021 FY
Q3 2020 $483,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $153,000 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $112,000 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1

Vor Biopharma Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $9,847,000 -$3,515,000 -26% 01 Jan 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
2023 $13,362,000 +$2,667,000 +25% 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
2022 $10,695,000 +$6,380,000 +148% 01 Jan 2022 31 Dec 2022 10-K 20 Mar 2024 2023 FY
2021 $4,315,000 +$2,973,000 +222% 01 Jan 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
2020 $1,342,000 01 Jan 2020 31 Dec 2020 10-K 14 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.